21 Recruiting Multiple Myeloma Clinical Trials in Massachusetts
Explore active multiple myeloma research studies enrolling across Massachusetts. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Multiple Myeloma Studies in Massachusetts
Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔KRDI in Transplant-Eligible MM
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔CAR- PRISM (PRecision Intervention Smoldering Myeloma)
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔TriPRIL CAR T Cells in Multiple Myeloma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔Biomarker for Infection Risk in CLL and MM
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Boston, Massachusetts
View Study & Checklist ➔Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
View Study & Checklist ➔ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Collection of Samples and Clinical Data From Patients With Amyloid Diseases
📍 Boston University Cancer Research Center — Boston, Massachusetts
View Study & Checklist ➔A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
📍 Tufts Medical Center (Data Collection Only) — Boston, Massachusetts
View Study & Checklist ➔A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔